ImClone rejects ultimatum
ImClone Systems Inc has rejected demands by Bristol-Mysers Squibb Co. to restructure its $2 billion agreement to develop and market a cancer drug. But Bristol-Myers did not immediately carry through
ImClone Systems Inc has rejected demands by Bristol-Mysers Squibb Co. to restructure its $2 billion agreement to develop and market a cancer drug. But Bristol-Myers did not immediately carry through